Develops rare-disease drug candidates, including setrusumab and alvelestat, for pharmaceutical and biotechnology partners.
10-K for FY2025, filed Mar 19, 2026
Mereo licenses drug-candidate rights to pharmaceutical and biotechnology partners and can receive upfront fees, research and development payments, milestone payments, and royalties on product sales. Upfront license fees are paid when the partner receives the license; milestone payments depend on reaching agreed development, regulatory, or sales goals.
10-K for FY2025, filed Mar 19, 2026The Company’s ongoing major or central operations are the development of product candidates to key clinical milestones and either…View ↗
The terms of these arrangements typically include payment to the Company of one or more of the following: nonrefundable, upfront license…View ↗
If a license to the Company's intellectual property is determined to be distinct from the other performance obligations identified in the…View ↗
$500K
10-K for FY2025, filed Mar 19, 2026
$500K ↗
Pharmaceutical and biotechnology companies take licenses or collaborate directly with Mereo on drug candidates, with rights covering worldwide or specified territories.
10-K for FY2025, filed Mar 19, 2026The Company’s ordinary business activities are the development of product candidates to key clinical milestones and either strategically…View ↗
The Company’s ongoing major or central operations are the development of product candidates to key clinical milestones and either…View ↗
The following table summarizes our pipeline for our core product candidates. We have global commercial rights to alvelestat, commercial…View ↗
No. It lost $41.9M in FY2025.
10-Q for Q3 FY2026, filed Nov 9, 2026
−$5.9MView ↗
8-K, filed Aug 19, 2026
On August 18, 2026, the Company received a second notice (the “Second Notice”) from the Staff indicating that, while the Company has not…View ↗
8-K, filed Aug 11, 2026
On August 11, 2026, Mereo BioPharma Group plc (the “Company” or "Mereo") entered into an Option and License Agreement (the “Agreement”)…View ↗
A tighter rare-disease focus
The older report described oncology candidates alongside rare-disease programs; the latest report frames the core pipeline around rare diseases, while etigilimab remains available for partnering.
20-F for FY2022, filed Mar 28, 2023 10-K for FY2025, filed Mar 19, 2026
Leflutrozole partnership
Leflutrozole moved from a candidate Mereo planned to partner or sell to a global license with ReproNovo, which holds worldwide rights and is responsible for future development and commercialization.
20-F for FY2022, filed Mar 28, 2023 10-K for FY2025, filed Mar 19, 2026We plan to partner or sell our other two product candidates acumapimod for the treatment of AECOPD and leflutrozole for the treatment of…View ↗
Competes with Amgen, UCB, Transcenta Holding, Eli Lilly and, BOOST Pharma, Angitia Biopharmaceuticals, Grifols, Shire, Takeda Pharmaceutical, CSL, Kamada, Sanofi, Wave Life Sciences, Beam Therapeutics, Krystal Biotech, Korro Bio, Roche, Merck, iTeos, and GSK
10-K for FY2025, filed Mar 19, 2026We consider setrusumab’s current closest potential competitors in development for the treatment of OI to be Amgen and UCB’s anti-sclerostin…View ↗
Loading...